Prostate Cancer Coverage from Every Angle

Daniel P. Petrylak, MD, on Understanding ARV-110, an Oral PROTAC Degrader for Prostate Cancer Treatment

Posted: Tuesday, July 7, 2020

Daniel P. Petrylak, MD, of the Yale Cancer Center, discusses the proteolysis–targeting chimera degrader ARV-110, which shows antitumor activity in metastatic castration-resistant prostate cancer after other treatments, and describes next steps in the development of this agent.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.